Background and Objectives Patients with spinal cord injury (SCI) commonly experience
central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for …

Purpose Mirogabalin besylate has been approved in several countries to treat peripheral
neuropathic pain. This pooled analysis, using data from the two pivotal Phase III studies in …

Introduction This study was performed to explore the efficacy and safety of pregabalin and
gabapentin in patients with spinal cord injury (SCI)-induced neuropathic pain to determine …

Objective: Pregabalin has been approved for the treatment of the neuropathic pain following
spinal cord injury (SCI). We performed a systemic review and meta-analysis of randomized …

Objective: To assess the efficacy and tolerability of pregabalin for the treatment of central
neuropathic pain after spinal cord injury (SCI). Methods: Patients with chronic, below-level …

Objective: To evaluate pregabalin in central neuropathic pain associated with spinal cord
injury. Methods: A 12-week, multicenter study of patients randomized to either flexible-dose …

Background Management of neuropathic pain (NeP) associated with spinal cord injury (SCI)
is difficult. This report presents a systematic literature review and comparison of the efficacy …

Neuropathic pain after spinal cord injury (SCI) has a significant negative impact on the
patients' quality of life. The objective of this systematic review is to examine the safety and …

Objective: To summarize the efficacy and examine the safety and tolerability of pregabalin in
patients with central neuropathic pain due to spinal cord injury (SCI). Research design and …

Introduction Mirogabalin, which is a selective ligand of the α 2 δ subunit of voltage-gated Ca
2+ channels, was recently approved in Japan for peripheral neuropathic pain. The α 2 δ …